Targeting AKT and CK2 represents a novel therapeutic strategy for SMO constitutive activation-driven medulloblastoma.

Yue-Liang YaoYan-Xia WangFei-Cheng YangChuan WangMin MaoQu-Jing GaiJiang HeYan QinXiao-Xue YaoXi LanJiang ZhuHui-Min LuHui ZengXiao-Hong YaoXiu-Wu BianYan Wang

Published in: CNS neuroscience & therapeutics (2022)

Taken together, our work described SMO-related transcriptomes, metabolomes, and interactomes under different SMO status and treatment conditions, identifying CK2 and AKT as therapeutic targets for SHH-subtype MB cells with SMO inhibitor resistance.

Keyphrases

signaling pathway
induced apoptosis
cell proliferation
protein kinase
cell cycle arrest
single cell
cancer therapy
pi k akt
cell death